BioLife Solutions, Inc. Preferred Stock Dividends, Income Statement Impact
BioLife Solutions, Inc. (BLFS) reported Preferred Stock Dividends, Income Statement Impact of $339.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2020-05-15
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-12-31 was $60.00K, a 43.79% decline year-over-year.
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-09-30 was $80.00K, a 24.71% decline year-over-year.
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-06-30 was $93.00K.
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-03-31 was $106.00K.
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for fiscal 2018 was $339.00K, a 59.15% increase from fiscal 2017.
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for fiscal 2017 was $213.00K.
- BioLife Solutions, Inc. preferred stock dividends, income statement impact for fiscal 2016 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 3 month as first filed | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 6 month as first filed | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 9 month as first filed | Preferred Stock Dividends, Income Statement Impact 12 month | Preferred Stock Dividends, Income Statement Impact 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $60.00K derived: 10-K 12 month − 10-K 9 month · filed 2020-05-15 | $140.00K derived: sum of 2 quarters · filed 2020-05-15 | $233.00K derived: sum of 3 quarters · filed 2020-05-15 | $339.00K 10-K · filed 2020-05-15 | ||||
| 2018-09-30 | $80.00K 10-K · filed 2020-05-15 | $79.67K 10-Q · filed 2018-11-08 | $173.00K derived: sum of 2 quarters · filed 2020-05-15 | $279.00K 10-K · filed 2020-05-15 | $279.18K 10-Q · filed 2018-11-08 | $385.75K derived: sum of 4 quarters · filed 2020-05-15 | ||
| 2018-06-30 | $93.00K 10-K · filed 2020-05-15 | $93.26K 10-Q · filed 2018-08-09 | $200.00K 10-K · filed 2020-05-15 | $199.51K 10-Q · filed 2018-08-09 | $305.75K derived: sum of 3 quarters · filed 2020-05-15 | $412.00K derived: sum of 4 quarters · filed 2020-05-15 | ||
| 2018-03-31 | $106.00K 10-K · filed 2020-05-15 | $106.25K 10-Q · filed 2018-05-11 | $212.75K derived: sum of 2 quarters · filed 2020-05-15 | $319.00K derived: sum of 3 quarters · filed 2020-05-15 | ||||
| 2017-12-31 | $106.75K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $213.00K derived: sum of 2 quarters · filed 2019-03-15 | $213.00K 10-K · filed 2019-03-15 | $212.50K 10-K · filed 2018-03-09 | ||||
| 2017-09-30 | $106.25K 10-Q · filed 2018-11-08 | $106.25K 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $0.00 derived: sum of 2 quarters · filed 2018-03-09 | $0.00 10-K · filed 2018-03-09 | |||||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |